BRPI0412380A - compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos - Google Patents

compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos

Info

Publication number
BRPI0412380A
BRPI0412380A BRPI0412380-8A BRPI0412380A BRPI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A
Authority
BR
Brazil
Prior art keywords
compounds
disease
pharmaceutical compositions
compositions containing
type
Prior art date
Application number
BRPI0412380-8A
Other languages
English (en)
Inventor
Thalaththani Ralalag Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412380A publication Critical patent/BRPI0412380A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE BENZENOSSULFONILAMINO E COMPOSIçõES FARMACêUTICAS QUE CONTêM ESSES COMPOSTOS". A presente invenção refere-se a compostos de fórmula (I) que proporcionam agentes farmacológicos que se ligam a Receptores Ativados por Proliferadores de Peroxissoma (PPARs). Conseqüentemente, os compostos da presente invenção são úteis para o tratamento de condições mediadas pela atividade de receptor PPAR em mamíferos. Essas condições incluem dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerose, hipertrigliceridemia, insuficiência cardíaca, infarto do miocárdio, doenças vasculares, doenças cardiovasculares, hipertensão, obesidade, inflamação, artrite, câncer, doença de Alzheimer, distúrbios da pele, doenças respiratórias, distúrbios oftálmicos, doenças inflamatórias intestinais (IBDs), colite ulcerativa e doença de Crohn, e condições em que tolerância a glicose prejudicada, hiperglicemia e resistência à insulina estão implicadas, tais como diabetes tipo 1 e tipo 2, e Síndrome X.
BRPI0412380-8A 2003-07-08 2004-07-07 compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos BRPI0412380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48587003P 2003-07-08 2003-07-08
PCT/EP2004/007442 WO2005005421A1 (en) 2003-07-08 2004-07-07 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
BRPI0412380A true BRPI0412380A (pt) 2006-09-19

Family

ID=34062103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412380-8A BRPI0412380A (pt) 2003-07-08 2004-07-07 compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos

Country Status (9)

Country Link
US (1) US7538135B2 (pt)
EP (1) EP1646628A1 (pt)
JP (1) JP2009513523A (pt)
CN (1) CN100447139C (pt)
AU (1) AU2004255342C1 (pt)
BR (1) BRPI0412380A (pt)
CA (1) CA2531418A1 (pt)
MX (1) MXPA06000118A (pt)
WO (1) WO2005005421A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
JP2008542355A (ja) 2005-05-31 2008-11-27 ファイザー株式会社 Ｖｒ１アンタゴニストとしての置換アリールオキシ−ｎ−ビシクロメチルアセトアミド化合物
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
BRPI0616872A2 (pt) 2005-10-06 2011-07-05 Sanofi Aventis [1,3,4]-tiadiazol-2il-amidas de ácido aril-sulfÈnico bicìclico, produto farmacêutico compreendendo os mesmos, uso e processo para a preparação do referido produto farmacêutico
CN101282951A (zh) 2005-10-06 2008-10-08 塞诺菲-安万特股份有限公司 N-[1,3,4]-噻二唑-2-基-苯磺酰胺，其制备方法以及其作为药物的应用
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
EP2054397B1 (en) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
DK2420494T3 (en) * 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
WO2009080223A1 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EP2485731B1 (en) * 2009-10-06 2016-05-11 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN101774922B (zh) * 2010-01-29 2012-12-26 浙江大学 2,3-二羟基苯甲酸酯类化合物及制备和应用
ES2659343T3 (es) 2011-07-20 2018-03-14 The Regents Of The University Of California Dispositivo de poro dual
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL2839232T3 (pl) 2012-04-16 2020-04-30 Pyrotek Inc. Urządzanie do zanurzania stapianego złomu metalowcgo
EP2931280B1 (en) 2012-12-14 2018-02-14 Phusis Therapeutics Inc. Methods and compositions for inhibiting cnksr1
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA036075B1 (ru) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB2533136A (en) * 2014-12-11 2016-06-15 Antabio Sas Compounds
WO2016172191A1 (en) 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053227B1 (en) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
AU2852100A (en) * 1999-01-19 2000-08-29 Tularik Inc. Methods of modulating uric acid levels
EP1177187B1 (en) * 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
US6298255B1 (en) * 1999-06-09 2001-10-02 Aspect Medical Systems, Inc. Smart electrophysiological sensor system with automatic authentication and validation and an interface for a smart electrophysiological sensor system
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
CN1171872C (zh) * 1999-06-30 2004-10-20 图拉列克股份有限公司 调节PPARγ活性的化合物
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN1816546A (zh) 2006-08-09
CA2531418A1 (en) 2005-01-20
CN100447139C (zh) 2008-12-31
EP1646628A1 (en) 2006-04-19
US20070043020A1 (en) 2007-02-22
MXPA06000118A (es) 2006-04-27
WO2005005421A1 (en) 2005-01-20
AU2004255342C1 (en) 2009-05-14
AU2004255342A1 (en) 2005-01-20
JP2009513523A (ja) 2009-04-02
US7538135B2 (en) 2009-05-26
AU2004255342B2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0412380A (pt) compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
BRPI0410779A (pt) heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma
BR0214305A (pt) Compostos heterocìclicos e métodos de uso
BRPI0414536A (pt) compostos orgánicos
CO2021008089A2 (es) Agonistas de glp-1r y usos de los mismos
AR123156A1 (es) Agonistas de glp-1r y sus usos
BRPI0518425A2 (pt) composiÇço farmacÊutica compreendendo Ácidos graxos âmega-3 e agonista e/ou antagonista ppar e composiÇço farmacÊutica em forma de dose unitÁria compreendendo fenofibrato e sistema solvente
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
DE602006008576D1 (de) Antidiabetische bicyclische verbindungen
MX2022005886A (es) Agonista del receptor glp-1 y uso de este.
CY1121423T1 (el) Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου
CL2008002351A1 (es) Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
MX2016015182A (es) Compuestos triciclicos antidiabeticos.
PE20050249A1 (es) Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
BRPI1013645A2 (pt) conjugado de fármaco anticorpo e sua composição farmacêutica
CR9644A (es) Agonistas del receptor de la hormonatiroidea
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
BRPI0307355C1 (pt) composto de 2,4-pirimidinodiamina, e, composição farmacêutica compreendendo o mesmo
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
EP2401263A4 (en) SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MX2022015500A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
BRPI0515992A (pt) compostos e métodos para o tratamento de resistência à insulina e cardiomiopatia

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.